HUE060655T2 - Új alkilálási reagens - Google Patents

Új alkilálási reagens

Info

Publication number
HUE060655T2
HUE060655T2 HUE19184082A HUE19184082A HUE060655T2 HU E060655 T2 HUE060655 T2 HU E060655T2 HU E19184082 A HUE19184082 A HU E19184082A HU E19184082 A HUE19184082 A HU E19184082A HU E060655 T2 HUE060655 T2 HU E060655T2
Authority
HU
Hungary
Prior art keywords
alkylating agents
new alkylating
new
agents
alkylating
Prior art date
Application number
HUE19184082A
Other languages
English (en)
Hungarian (hu)
Inventor
Italo Beria
Michele Caruso
Vittoria Lupi
Paolo Orsini
Matteo Salsa
Achille Panzeri
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HUE060655T2 publication Critical patent/HUE060655T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE19184082A 2012-04-05 2013-03-28 Új alkilálási reagens HUE060655T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12163459 2012-04-05
EP12176162 2012-07-12

Publications (1)

Publication Number Publication Date
HUE060655T2 true HUE060655T2 (hu) 2023-04-28

Family

ID=48092927

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19184082A HUE060655T2 (hu) 2012-04-05 2013-03-28 Új alkilálási reagens

Country Status (11)

Country Link
US (2) US9527863B2 (fr)
EP (2) EP3587426B1 (fr)
JP (2) JP6314128B2 (fr)
CN (2) CN107011358B (fr)
DK (1) DK2836494T3 (fr)
ES (2) ES2929759T3 (fr)
HK (1) HK1203957A1 (fr)
HR (1) HRP20221356T1 (fr)
HU (1) HUE060655T2 (fr)
RU (1) RU2632206C2 (fr)
WO (1) WO2013149948A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836493B1 (fr) * 2012-04-05 2018-06-20 Nerviano Medical Sciences S.r.l. Dérivés de thiéno-indole fonctionnalisés pour le traitement du cancer
US9527863B2 (en) 2012-04-05 2016-12-27 Nerviano Medical Sciences S.R.L. Thieno-indole moieties and methods of treating using the same
US10266547B2 (en) * 2013-09-25 2019-04-23 Nerviano Medical Sciences S.R.L. Thieno[2,3-e]indole derivatives as new antitumor agents
AU2016238551B2 (en) 2015-03-20 2020-01-02 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore
US10174048B2 (en) * 2015-07-21 2019-01-08 Nerviano Medical Sciences S.R.L. Asymmetric process for the preparation of thieno-indoles derivatives
JP6412906B2 (ja) 2015-11-03 2018-10-24 財團法人工業技術研究院Industrial Technology Research Institute 化合物、リンカー−薬物およびリガンド−薬物複合体
KR102493853B1 (ko) * 2016-08-19 2023-01-30 브리스톨-마이어스 스큅 컴퍼니 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법
WO2022053570A1 (fr) * 2020-09-09 2022-03-17 Clinuvel Pharmaceuticals Ltd (Uk) Composés pyrrolidine pour le traitement de la xeroderma pigmentosum

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065393B1 (fr) * 1981-05-12 1984-12-27 Imperial Chemical Industries Plc Dérivés du pyrrole
CA1238907A (fr) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo (3,2-e)-indol-4(5h)-ones et composes apparentes
US5659022A (en) * 1996-01-05 1997-08-19 Epoch Pharmaceuticals, Inc. Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids
JP3045706B1 (ja) 1998-09-14 2000-05-29 科学技術振興事業団 Dnaの特定塩基配列をアルキル化する化合物及びその合成法
GB2344818A (en) 1998-12-16 2000-06-21 Pharmacia & Upjohn Spa Anti-tumour thieno-indole derivatives
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
EP1243276A1 (fr) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Prodrogues activables à séparateurs allongés et multiples
WO2002096910A1 (fr) * 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxines, promedicaments, lieurs et stabilisateurs utiles pour ceux-ci
EP1423110A4 (fr) * 2001-09-07 2005-04-27 Scripps Research Inst Analogues cbi de cc-1065 et des duocarmycines
WO2003026577A2 (fr) * 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-aminobenzyl ether dans des agents d'administration de medicaments
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
CA2506080A1 (fr) 2002-11-14 2004-05-27 Syntarga B.V. Promedicaments concus en tant qu'espaceurs de liberation multiple a elimination automatique
WO2004069201A2 (fr) * 2003-02-03 2004-08-19 Medlogics Device Corporation Composes utiles pour enduire des stents pour la prevention et le traitement de la stenose et de la restenose
TW200526204A (en) * 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
US7282590B2 (en) 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
CN1997399A (zh) 2004-04-21 2007-07-11 阿尔扎公司 可在温和硫解条件下释放的聚合物共轭物
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1789391B1 (fr) 2004-07-23 2017-06-28 Endocyte, Inc. Groupes de liaison bivalents et conjugués de ceux-ci
CA2641899A1 (fr) * 2006-02-02 2007-08-09 Syntarga B.V. Analogues de cc-1065 hydrosolubles et leurs conjugues
BRPI0720589A2 (pt) * 2006-12-20 2014-02-25 Nerviano Medical Sciences Srl Derivados de indazol como inibidores da quinase para tratamento do câncer, derivados de indazol como inibidores da quinase para tratamento do câncer
KR101667062B1 (ko) 2008-07-15 2016-10-17 제넨테크, 인크. 안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도
US9527863B2 (en) 2012-04-05 2016-12-27 Nerviano Medical Sciences S.R.L. Thieno-indole moieties and methods of treating using the same
EP2836493B1 (fr) * 2012-04-05 2018-06-20 Nerviano Medical Sciences S.r.l. Dérivés de thiéno-indole fonctionnalisés pour le traitement du cancer

Also Published As

Publication number Publication date
US9527863B2 (en) 2016-12-27
EP2836494A1 (fr) 2015-02-18
US10071074B2 (en) 2018-09-11
WO2013149948A1 (fr) 2013-10-10
ES2755719T3 (es) 2020-04-23
US20170071907A1 (en) 2017-03-16
EP3587426B1 (fr) 2022-08-10
HK1203957A1 (en) 2015-11-06
ES2929759T3 (es) 2022-12-01
JP2018070599A (ja) 2018-05-10
CN104220442A (zh) 2014-12-17
CN107011358B (zh) 2020-05-05
CN107011358A (zh) 2017-08-04
JP2015514101A (ja) 2015-05-18
HRP20221356T1 (hr) 2022-12-23
EP2836494B1 (fr) 2019-08-21
US20150051154A1 (en) 2015-02-19
DK2836494T3 (da) 2019-11-11
CN104220442B (zh) 2016-11-23
JP6314128B2 (ja) 2018-04-18
RU2632206C2 (ru) 2017-10-03
RU2014143994A (ru) 2016-05-27
EP3587426A1 (fr) 2020-01-01

Similar Documents

Publication Publication Date Title
HK1209332A1 (en) Apoptosis-inducing agents
EP2814472A4 (fr) Agents réducteurs dithioamine
DK3327112T3 (en) Agse-deficient stamme
EP2934531A4 (fr) Combinaison
EP2754580A4 (fr) Camion-benne
DK2830816T3 (en) Hidtil ukendt coatingkoncept
EP2935220A4 (fr) Péri-carbinols
EP2823830A4 (fr) Agent d'élévation de la muqueuse
HK1203957A1 (en) New alkylating agents
EP2911673A4 (fr) Combinaison
EP2920142A4 (fr) Méthanofullerrènes
HK1204445A1 (en) Surrobody cojugates surrobody
EP2812698A4 (fr) Fret à résolution temporelle et accepteur double
SG11201503816PA (en) Alkylating process
EP2920157A4 (fr) Di-macrocycles
EP2873363A4 (fr) Diopsimètre
GB2518803B (en) Headshaft
GB2506332B (en) Aerobars
GB2500883B (en) Improved saw-horse
EP2834250A4 (fr) Silicates de lithium
EP2925728A4 (fr) Combinaison
EP2908815A4 (fr) Combinaison
EP2908816A4 (fr) Association
ZA201305187B (en) Improved brattice
GB201220591D0 (en) Improved soap